MVX-220 for Angelman syndrome earns FDA fast track status
The U.S. Food and Drug Administration (FDA) has granted fast track designation to MVX-220, Mavrix Bio’s investigational gene therapy for Angelman syndrome that is headed into clinical trials. Fast track designation aims to facilitate the clinical development and regulatory review of therapies intended to treat serious conditions with an…